Information regarding this study is available at the U.S. government's clinical trials database at http://www.clinicaltrials.gov.
About Heart Failure
Heart failure (HF) is a chronic condition in which the heart cannot effectively pump enough blood to the body's other organs, either as a result of impaired contractility (systolic heart failure) or impaired relaxation and ventricular filling (diastolic heart failure). HF is a major and growing public health problem affecting 5.3 million Americans, with over 650,000 new cases diagnosed every year. The annual mortality rate for heart failure is 19%. Treatment of Heart Failure generates annual costs of approximately $35 billion, of which approximately $3 billion is spent on drugs and $19 billion is spent in the acute hospital setting. Heart Failure patients frequently suffer episodes of acute decompensated heart failure (ADHF) which require hospitalization. For Americans over 65 years of age, ADHF is the most frequent cause of hospital admission. In recent years, 2.4 million patients in the US were hospitalized with a primary or secondary discharge code of ADHF with an average hospital stay of 4.3 days.
CD-NP is a novel chimeric natriuretic peptide in clinical development
for the treatment of ADHF. CD-NP was rationally designed by scientists at
the Mayo Clinic's Cardiorenal Research Labs. Current therapies for ADHF,
including B-type natriuretic peptide, have been associated with favorable
|SOURCE Nile Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved